Russian drug Pembroria for cancer treatment is licensed by the Ministry of Health for circulation in Vietnam. In response to the above information, on November 13, K Hospital officially informed about the circulation of Pembroria cancer treatment drug ( pembrolizumab active ingredient).
Accordingly, Pembrolizumab is the active ingredient invented by the American company MSD with the trade name Keytruda, bottle 100mg/4ml. Pembrolizumab is an antibodies of the anti class PD-1 and is a biological drug prescribed for certain types of cancer, belonging to the group of immune treatments. The drug is used by vein infusion at medical facilities.
Keytruda has been licensed for circulation in Vietnam by the Department of Drug Administration (Ministry of Health) since 2017. Currently, Keytruda has been approved by the Ministry of Health for 14 conditions including: Malignant haematcts, non-cellulitis lung cancer, classical lympho Hodgkin's tumor, urinary tract thyroid cancer, scalp and neck cancer, stomach cancer, cancer with high-level satellite instability, cervical cancer, liver cell carcinoma, colorectal cancer with high-level or defective patchwork repair, primary B-cellide lumpy cell growth factor, Esophageal cancer, negative tricuspid cancer, kidney cell tissue cancer.
The current price of Keytruda drugs is about 62 million VND/dose. The drug has a partially free support program for eligible cancer patients according to Decision No. 2205/QD-BYT dated July 2, 2025 of the Ministry of Health. The above support program is being implemented at K Hospital and many other hospitals nationwide. With this program, the maximum cost for a patient's treatment cycle is about 62 million VND with a 200mg (2 bottles) dose and some cycles can be completely free, depending on the level of support that the patient is approved for.
On October 31, 2025, the Drug Administration of Vietnam (Ministry of Health) issued a circulation registration certificate for Pembroria with the active ingredient pembrolizumab, bottle 100mg/4ml produced by Liability Company Limited "PK-137", Russian Federation.
Pembroria is a bioactive drug that is the same as Keytruda, approved for the following specifications: Haemorrhoids, non-cellulitis lung cancer, Scalp and neck cancer, Classical lympho Hodgkin, U-urel cancer, Esophageal cancer, cancer with highly-ursue immunosterio-nhyloid Agency (MSI-H) or impaired paternity, Cervical cancer, renal cell carcinoma, Endometriosis cancer, negative tricuspid cancer, Stomach-uc mo mo motedopathy cancer, Gastroenterological or culinary cancer, mat motedopathy cancer.
The expected price of Pembroria is about 18 million VND/ capsules, with the usual dose being 2 bottles for 1 treatment cycle. Thus, the cost for a patient's treatment cycle is about 36 million VND with a 200mg dose (2 bottles). Currently, K Hospital is planning to deploy the procurement of Pembroria drugs to put them into use for patients in the near future.
Not all patients with the above-mentioned cancers are prescribed pembrolizumab. The use of pembrolizumab also depends on many factors such as: The patient's condition, type of tumor complication, stage of disease... as assessed by cancer specialists.
At K Hospital, treatment will be personalized for each patient, based on many factors, the doctor will advise and provide a suitable regimen to ensure effective treatment for patients.
